Article Information
History
- August 29, 2021.
Article Versions
- You are currently viewing Version 1 of this article (August 29, 2021 - 15:50).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Kevin L. Winthrop1,
- Alan W. Skolnick2,
- Adnan M. Rafiq3,
- Scott H. Beegle4,
- Julian Suszanski5,
- Guenther Koehne6,
- Ofra Barnett-Griness7,
- Aida Bibliowicz8,
- Reza Fathi8,
- Patricia Anderson8,
- Gilead Raday8,
- Gina Eagle9,
- Vered Katz Ben-Yair8,
- Harold S. Minkowitz2,
- Mark L. Levitt10,* and
- Michael S. Gordon11
- 1Oregon Health & Sci. Univ., Portland, OR
- 2HD Res., Houston, TX
- 3Mem. Hermann Southeast Hosp., Houston, TX
- 4Albany Med. Coll., Albany, NY
- 5Henry Ford Hosp., Detroit, MI
- 6Miami Cancer Inst., Miami, FL
- 7Bioforum Ltd., Ness Ziona, Israel
- 8RedHill Biopharma Ltd., Tel-Aviv, Israel
- 9G.E.T Pharma Consulting LLC, Lambertville, NJ
- 10Levitt Oncology Associates Ltd., Hashmonaim, Israel
- 11Honor Health Res. Inst., Scottsdale, AZ
- ↵*Corresponding author: Mark L. Levitt, E-mail: mark{at}redhillbio.com, Phone: +972-(0)58-760-1010, Fax: +972-(0)3-541-3144
Posted August 29, 2021.
Opaganib in COVID-19 pneumonia: Results of a randomized, placebo-controlled Phase 2a trial
